Literature DB >> 16579820

Evaluating disease management programme effectiveness: an introduction to the regression discontinuity design.

Ariel Linden1, John L Adams, Nancy Roberts.   

Abstract

Although disease management (DM) has been in existence for over a decade, there is still much uncertainty as to its effectiveness in improving health status and reducing medical cost. The main reason is that most programme evaluations typically follow weak observational study designs that are subject to bias, most notably selection bias and regression to the mean. The regression discontinuity (RD) design may be the best alternative to randomized studies for evaluating DM programme effectiveness. The most crucial element of the RD design is its use of a 'cut-off' score on a pre-test measure to determine assignment to intervention or control. A valuable feature of this technique is that the pre-test measure does not have to be the same as the outcome measure, thus maximizing the programme's ability to use research-based practice guidelines, survey instruments and other tools to identify those individuals in greatest need of the programme intervention. Similarly, the cut-off score can be based on clinical understanding of the disease process, empirically derived, or resource-based. In the RD design, programme effectiveness is determined by a change in the pre-post relationship at the cut-off point. While the RD design is uniquely suitable for DM programme evaluation, its success will depend, in large part, on fundamental changes being made in the way DM programmes identify and assign individuals to the programme intervention.

Entities:  

Mesh:

Year:  2006        PMID: 16579820     DOI: 10.1111/j.1365-2753.2005.00573.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  7 in total

1.  Evidence from regression-discontinuity analyses for beneficial effects of a criterion-based increase in alcohol treatment.

Authors:  Rosely Flam-Zalcman; Robert E Mann; Gina Stoduto; Thomas H Nochajski; Brian R Rush; Anja Koski-Jännes; Christine M Wickens; Rita K Thomas; Jürgen Rehm
Journal:  Int J Methods Psychiatr Res       Date:  2012-11-20       Impact factor: 4.035

2.  A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.

Authors:  Marc L Berger; Bradley C Martin; Don Husereau; Karen Worley; J Daniel Allen; Winnie Yang; Nicole C Quon; C Daniel Mullins; Kristijan H Kahler; William Crown
Journal:  Value Health       Date:  2014-03       Impact factor: 5.725

3.  ESTIMATING MARGINAL RETURNS TO MEDICAL CARE: EVIDENCE FROM AT-RISK NEWBORNS.

Authors:  Douglas Almond; Joseph J Doyle; Amanda E Kowalski; Heidi Williams
Journal:  Q J Econ       Date:  2010-05-01

Review 4.  Advancing Quality Improvement with Regression Discontinuity Designs.

Authors:  Allan J Walkey; Mari-Lynn Drainoni; Nicholas Cordella; Jacob Bor
Journal:  Ann Am Thorac Soc       Date:  2018-05

5.  Approaches to the Estimation of the Local Average Treatment Effect in a Regression Discontinuity Design.

Authors:  Aidan G O'Keeffe; Gianluca Baio
Journal:  Scand Stat Theory Appl       Date:  2016-03-22       Impact factor: 1.396

6.  Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom.

Authors:  Arianne M J Elissen; John L Adams; Marieke Spreeuwenberg; Inge G P Duimel-Peeters; Cor Spreeuwenberg; Ariel Linden; Hubertus J M Vrijhoef
Journal:  BMC Med Res Methodol       Date:  2013-03-14       Impact factor: 4.615

Review 7.  Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA).

Authors:  Maureen Rutten-van Mölken; Fenna Leijten; Maaike Hoedemakers; Apostolos Tsiachristas; Nick Verbeek; Milad Karimi; Roland Bal; Antoinette de Bont; Kamrul Islam; Jan Erik Askildsen; Thomas Czypionka; Markus Kraus; Mirjana Huic; János György Pitter; Verena Vogt; Jonathan Stokes; Erik Baltaxe
Journal:  BMC Health Serv Res       Date:  2018-07-24       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.